Company intelligence / Profile preview
Shanghai Yuanxi Pharmaceutical Technology
Shanghai, Shanghai Shi, Chinayxmedicine.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai Yuanxi Pharmaceutical Technology is a clinical-stage biotech company focused on developing first-in-class small molecule drugs targeting novel mechanisms for fibrosis, cancer, and other significant diseases. Its lead asset, butaselen—a TrxR inhibitor—is in Phase 2 clinical trials for cryptogenic organizing pneumonia and idiopathic interstitial pneumonias[1][9]. The company claims full ownership of domestic and international intellectual property for its assets[1].
- Therapeutic areas
- PulmonologyOncologyOther
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Shanghai Yuanxi Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Yuanxi Pharmaceutical Technology.